MELANOMA OF UNKNOWN PRIMARY
Clinical trials for MELANOMA OF UNKNOWN PRIMARY explained in plain language.
Never miss a new study
Get alerted when new MELANOMA OF UNKNOWN PRIMARY trials appear
Sign up with your email to follow new studies for MELANOMA OF UNKNOWN PRIMARY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo therapy shows promise in shrinking melanoma before surgery
Disease control OngoingThis study tests whether adding an experimental drug (CMP-001) to the immunotherapy pembrolizumab can better shrink melanoma tumors before surgery and help prevent the cancer from coming back. About 60 adults with stage III or recurrent melanoma that can be surgically removed wil…
Matched conditions: MELANOMA OF UNKNOWN PRIMARY
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 03:09 UTC
-
Major trial tests which immune drug best stops melanoma comeback
Disease control OngoingThis study tested whether the immunotherapy drug ipilimumab works better than high-dose interferon alfa-2b at preventing melanoma from coming back after surgery. About 1,673 patients with high-risk stage III–IV melanoma that was fully removed took part. The main goal was to see w…
Matched conditions: MELANOMA OF UNKNOWN PRIMARY
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 15, 2026 11:53 UTC
-
Melanoma patients may get a break from therapy thanks to PET scans
Disease control OngoingThis study looks at whether doctors can safely stop standard anti-PD-1 immunotherapy early in people with advanced melanoma that cannot be surgically removed. Using PET/CT scans and tumor biopsies as guides, the goal is to see if stopping treatment sooner still keeps the cancer u…
Matched conditions: MELANOMA OF UNKNOWN PRIMARY
Phase: PHASE2 • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Disease control
Last updated May 14, 2026 12:03 UTC